BIOS — Bioservo Technologies AB Income Statement
0.000.00%
- SEK1.60m
- -SEK17.28m
- SEK9.64m
Annual income statement for Bioservo Technologies AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.71 | 9.27 | 11.7 | 7.1 | 9.64 |
Cost of Revenue | |||||
Gross Profit | 5.92 | 5.12 | 5.08 | 1.95 | 2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 28.9 | 32.5 | 38 | 41.8 | 60.2 |
Operating Profit | -22.2 | -23.2 | -26.3 | -34.7 | -50.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22.2 | -23.2 | -26.3 | -34.7 | -50.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -27.9 | -23.2 | -26.3 | -34.7 | -50.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -27.9 | -23.2 | -26.3 | -34.7 | -50.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -27.9 | -23.2 | -26.3 | -34.7 | -50.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.6 | -2.34 | -2.13 | -2.08 | -2.54 |
Dividends per Share |